Long-Term Maintenance of Complete Response after Sorafenib Treatment for Multiple Lung Metastases from Hepatocellular Carcinoma

Eisuke Katafuchi  Yuko Takami  Yoshiyuki Wada  Masaki Tateishi  Tomoki Ryu  Kazuhiro Mikagi  Hideki Saitsu
Department of Hepato-Biliary-Pancreatic Surgery, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan

Key Words
Hepatocellular carcinoma · Sorafenib · Complete response · Lung metastases · Liver · Chemotherapy

Abstract
Sorafenib is an effective treatment for unresectable hepatocellular carcinoma (HCC) characterized by disease stabilization. However, the response rates are very low (<9%), and a complete response is rarely achieved. We report an extremely rare case of a HCC patient with multiple lung metastases treated with sorafenib who achieved a complete response for a long period. A 77-year-old woman was diagnosed with chronic hepatitis C in 1990. In 2007, a HCC detected in the liver was treated with percutaneous ethanol injection therapy. Subsequently, recurrence of HCC in the liver was treated with microwave coagulonecrotic therapy in 2010. In April 2011, a computed tomography (CT) scan revealed innumerable multiple metastases spread diffusely in both lungs. Tumor marker levels were extremely high [α-fetoprotein (AFP) 76,170 ng/ml, lens culinaris agglutinin-reactive fraction of AFP 7.5%, des-γ-carboxyprothrombin (DCP) 63,400 mAU/ml]. Sorafenib was administered at a reduced dose of 400 mg/day because of old age. Four months after sorafenib treatment, AFP and DCP had decreased to within normal levels, and the multiple lung metastases had disappeared. Currently, sorafenib is administered at a reduced dose of 400 mg/day, and the complete response has been maintained for 48 months.
Introduction

Hepatocellular carcinoma (HCC) is one of the most common cancers in the world [1]. Sorafenib, an oral molecular-targeted drug, has become the standard therapy for advanced HCC (i.e., extrahepatic metastases, unresectable or not eligible for locoregional therapy) [2]. Sorafenib is a multiple kinase inhibitor which affects tumor proliferation and angiogenesis by inhibiting Raf-1, B-Raf kinase, vascular endothelial growth factor receptor 1, 2 and 3, platelet-derived growth factor receptor β, Flt-3 and c-KIT 2.

Two recent double-blind randomized phase III trials, the Sorafenib HCC Randomized Protocol (SHARP) [2] and the Asian-Pacific Trial [3], have shown improvement in overall survival after sorafenib treatment; in addition, sorafenib is believed to be particularly effective for distant metastasis. However, the partial response was low at 2–5%, and there were no cases of complete response (CR) among the 449 patients treated with sorafenib in these trials. Therefore, sorafenib has been considered as a disease stabilizer.

Herein, we report a very rare case treated with sorafenib for HCC with multiple lung metastases resulting in a CR that has been maintained for 48 months.

Case Report

A 77-year-old Japanese female was diagnosed with chronic hepatitis C in 1990. A HCC (13 × 10 mm) was detected in segment 7/8 on a computed tomography (CT) scan and treated with percutaneous ethanol injection therapy in April 2007. Subsequently, recurrence of the HCC (23 × 13 mm) was observed in December 2010 in the same segment, and microwave coagulation therapy was performed. In April 2011, a chest X-ray image and CT scan revealed multiple lung metastases (fig. 1a). No brain or bone metastases could be detected.

Laboratory test results at the time of diagnosis were as follows: albumin 2.9 g/dl, aspartate aminotransferase 30 IU/l, alanine aminotransferase 15 IU/l, total bilirubin 0.5 mg/dl and prothrombin international normalized ratio 1.05. The patient had good reserve liver function with a Child-Pugh score of 6 (Child-Pugh class A) and did not have any ascites or findings of encephalopathy. Tumor markers such as α-fetoprotein (AFP; 76,170 ng/ml), the lens culinaris agglutinin-reactive fraction of AFP (7.5%) and des-γ-carboxyprothrombin (DCP; 63,400 mAU/ml) were elevated. Sorafenib administration was initiated at a reduced dose of 400 mg/day, because of the patient’s advanced age and low body mass index (BMI) of 19.7.

After 4 months of sorafenib administration, the tumor markers decreased to normal levels (AFP 7.5 ng/ml, DCP 30 mAU/ml), and the metastatic lung lesions had disappeared (fig. 1b). We considered that the patient had achieved a CR according to the RECIST evaluation. The patient continues to be treated with sorafenib at a reduced dose of 400 mg/day without adverse effects and is still maintaining a CR.

Discussion

The present patient represents a rare case involving multiple lung metastases, confirmed on the basis of imaging and tumor marker levels, who achieved a CR after treatment with sorafenib. Furthermore, it was unusual because the patient has maintained this CR for 48 months and has continued sorafenib treatment without adverse effects. There are 2 im-
Important points to note in our case: (1) the achievement of a CR and (2) long-term maintenance of the CR.

Sorafenib is usually used for disease stabilization, and its response rate is <9%. In a retrospective study that compared sorafenib responders (CR and partial response) and nonresponders (stable disease, progressive disease and nonprogressive disease), multiple lung metastases were frequently observed in responders to sorafenib [4]. Therefore, sorafenib seems to be effective in the treatment of extrahepatic metastasis, especially lung metastasis. Shiba et al. [5] reported that significant factors in their 18 Japanese cases involving a CR were sex (female), low body weight (<59 kg), early clinical stage and use of a small initial dose. The clinical characteristics of the 12 reported cases and our case that achieved a CR as a result of sorafenib treatment are detailed in Table 1 [6–17]. There were 6 (46%) lung metastasis cases. The data suggest that sorafenib is useful in the treatment of lung metastasis. Intrahepatic tumor stage seems unrelated to the rate of CR, because 8 out of 13 cases were at stage T3–4. AFP levels decreased by >20% in all cases presented in Table 1, but 9 out of 13 cases had an initial AFP level of ≥400 ng/dl. This indicates that the AFP response is a good prognostic factor regarding CR and also that it is possible to achieve a CR regardless of the initial AFP levels.

The number of males and females was 11 and 2, respectively. Interestingly, only 4 out of 13 cases had commenced treatment with sorafenib at a dose of 400 mg/day (Table 1). Elucidation of the characteristics of HCC patients who attained a CR after sorafenib treatment allows prediction of efficacy and survival outcome before the initiation of treatment. However, populations of patients who have achieved a CR are too small for definitive conclusions to be made. Further evaluation in future clinical studies is required.

Five out of 13 cases had maintained a CR for >10 months (Table 1). Two among these 5 cases exhibited multiple lung metastases. These findings suggest that a patient who has multiple lung metastases can be expected to achieve a long-term CR. It has been controversial as to whether or not sorafenib treatment should be continued after the diagnosis of a CR. In a previous study, 188 patients who had undergone sorafenib monotherapy were analyzed, and it was reported that patients who received sorafenib for >90 days showed a favorable outcome [18]. In fact, 3 out of 5 long-term CR patients detailed in table 1 continued sorafenib administration. Consequently, continuation of sorafenib treatment may be important in maintaining a long-term CR. The tolerability of sorafenib must be a limitation regarding continuation of the treatment. Actually, in most patients, the initial dose of sorafenib had been reduced because of adverse effects (Table 1). In the GIDEON study [19], the advantage of using a sorafenib dose of 800 mg/day had been demonstrated. However, a randomized control study carried out by the SOrafenib Italian Assessment (SOFIA) group compared initial doses of 400 mg/day and 800 mg/day. It was found that the therapy group that received the lower dose of 400 mg/day had a longer median survival time [20]. In our case, we started sorafenib treatment at a reduced dose of 400 mg/day because the patient was elderly and had a low BMI. As mentioned, the patient has been maintained on the same dose for >3 years without adverse effects.

In conclusion, multiple lung metastases and low body weight seem to be the characteristics required for the achievement of a long-term CR. The reason for the superiority regarding the use of a reduced initial dose of 400 mg/day remains unclear. However, our case suggests the possibility of achieving a long-term CR as a result of continuation of treatment with this dose of sorafenib. The limitation of this report is that the periods over which a CR was sustained in the cases detailed in table 1 might be underestimates; this is because many of the patients would have continued to maintain their CR after the date on which their data were
published. It remains important to accumulate and carefully analyze long-term CR cases in order to fully investigate the prognostic factors regarding sorafenib.

**Conclusion**

We have reported a case of innumerable multiple lung metastases of HCC keeping a CR for 48 months.

**Disclosure Statement**

The authors declare no conflicts of interest.

**References**

Katafuchi et al.: Long-Term Maintenance of Complete Response after Sorafenib Treatment for Multiple Lung Metastases from Hepatocellular Carcinoma


Table 1. Complete response in HCC patients treated with sorafenib

<table>
<thead>
<tr>
<th>First author</th>
<th>Age, years/sex</th>
<th>Etiology</th>
<th>Intrahepatic tumor stage (T stage)</th>
<th>Extrahepatic spread</th>
<th>Time to cessation</th>
<th>Time to CR</th>
<th>Administration period after CR, months</th>
<th>Reason of cessation</th>
<th>CR sustained period, months</th>
<th>AFP, ng/ml</th>
<th>AFP-L3, %</th>
<th>DCP, mAU/ml</th>
<th>Sorafenib initial dose, mg/day</th>
<th>Maintenance dose, mg/day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chelis [6]</td>
<td>69/M</td>
<td>HBV, HIV</td>
<td>3</td>
<td>lymph node</td>
<td>none</td>
<td>10 months</td>
<td>–</td>
<td>–</td>
<td>6</td>
<td>–</td>
<td>–</td>
<td>800</td>
<td>400</td>
<td></td>
</tr>
<tr>
<td>So [7]</td>
<td>78/M</td>
<td>Hemochromatosis</td>
<td>3</td>
<td>lung</td>
<td>6 months</td>
<td>5 months</td>
<td>1</td>
<td>clinical</td>
<td>6</td>
<td>13,599</td>
<td>–</td>
<td>800</td>
<td>800</td>
<td></td>
</tr>
<tr>
<td>Sacco [8]</td>
<td>84/M</td>
<td>HCV</td>
<td>3</td>
<td>none</td>
<td>none</td>
<td>6 months</td>
<td>–</td>
<td>–</td>
<td>6</td>
<td>353</td>
<td>–</td>
<td>800</td>
<td>800</td>
<td></td>
</tr>
<tr>
<td>Yeganeh [9]</td>
<td>54/M</td>
<td>HBV</td>
<td>0</td>
<td>lung</td>
<td>none</td>
<td>18 months</td>
<td>–</td>
<td>–</td>
<td>7</td>
<td>1.3</td>
<td>–</td>
<td>800</td>
<td>200</td>
<td></td>
</tr>
<tr>
<td>Kim [10]</td>
<td>66/M</td>
<td>alcohol</td>
<td>4</td>
<td>lymph node</td>
<td>12 months</td>
<td>6 months</td>
<td>6</td>
<td>financial</td>
<td>8</td>
<td>2,795</td>
<td>–</td>
<td>800</td>
<td>400</td>
<td></td>
</tr>
<tr>
<td>Inuzuka [11]</td>
<td>76/F</td>
<td>HCV</td>
<td>0</td>
<td>lung</td>
<td>4 months</td>
<td>3 months</td>
<td>1</td>
<td>liver dysfunction</td>
<td>8</td>
<td>6,952</td>
<td>–</td>
<td>187</td>
<td>400</td>
<td></td>
</tr>
<tr>
<td>Hagihara [12]</td>
<td>65/M</td>
<td>HCV</td>
<td>0</td>
<td>lung</td>
<td>21 days</td>
<td>3 months</td>
<td>0</td>
<td>ascites</td>
<td>8</td>
<td>55,607</td>
<td>–</td>
<td>11,302</td>
<td>400</td>
<td></td>
</tr>
<tr>
<td>Mizukami [13]</td>
<td>69/M</td>
<td>HCV</td>
<td>0</td>
<td>lymph node</td>
<td>11 days</td>
<td>3 months</td>
<td>0</td>
<td>hand foot syndrome</td>
<td>9</td>
<td>25.1</td>
<td>22.8</td>
<td>65</td>
<td>800</td>
<td>400</td>
</tr>
<tr>
<td>Koo [14]</td>
<td>74/M</td>
<td>unknown</td>
<td>4</td>
<td>none</td>
<td>none</td>
<td>9 months</td>
<td>–</td>
<td>–</td>
<td>10</td>
<td>33,058</td>
<td>–</td>
<td>800</td>
<td>200</td>
<td></td>
</tr>
<tr>
<td>Kudo [15]</td>
<td>68/M</td>
<td>HBV</td>
<td>3</td>
<td>lung</td>
<td>none</td>
<td>2 months</td>
<td>–</td>
<td>–</td>
<td>12</td>
<td>18,775</td>
<td>68.1</td>
<td>62621</td>
<td>800</td>
<td>400</td>
</tr>
<tr>
<td>Shinzawa [16]</td>
<td>68/M</td>
<td>HCV</td>
<td>4</td>
<td>none</td>
<td>2.4 years</td>
<td>2 years</td>
<td>4</td>
<td>patient’s request</td>
<td>16</td>
<td>4,773</td>
<td>60.5</td>
<td>17,400</td>
<td>800</td>
<td>400</td>
</tr>
<tr>
<td>Wang [17]</td>
<td>74/M</td>
<td>HCV</td>
<td>4</td>
<td>none</td>
<td>8 months</td>
<td>8 months</td>
<td>0</td>
<td>nausea, vomiting</td>
<td>16</td>
<td>3,300</td>
<td>–</td>
<td>400</td>
<td>400</td>
<td></td>
</tr>
<tr>
<td>Our case</td>
<td>77/F</td>
<td>HCV</td>
<td>0</td>
<td>lung</td>
<td>none</td>
<td>3 months</td>
<td>–</td>
<td>–</td>
<td>45</td>
<td>76,170</td>
<td>7.5</td>
<td>63,400</td>
<td>400</td>
<td>400</td>
</tr>
</tbody>
</table>

M = Male, F = female, HBV = hepatitis B virus, HIV = human immunodeficiency virus, HCV = hepatitis C virus.
Fig. 1. Chest CT images. a CT image at the initiation of sorafenib administration. Innumerable multiple lung metastases were revealed in both lungs. b CT image 4 months after sorafenib treatment. The multiple lung metastases disappeared in both lungs after sorafenib treatment.